Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Fulvestrant + Rapamycin (PI3K-Akt-mTOR) pathway inhibitors & Breast Cancer / Mammacarcinoma (HR + / HER2 -)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Compared with fulvestrant alone, the addition of PI3K/AKT/mTOR inhibitors significantly prolonged progression-free survival, overall survival and objective response rate of patients in both the total and PI3K-pathway-activated population. The number of grade 3–5 adverse events was also significantly higher.
Zhang et al. 2023a Future Oncology 19:…

References (Sources)

Addition of PI3K/AKT/mTOR inhibitors to fulvestrant for advanced HR+/HER2- breast cancer: a systematic review and meta-analysis
Zhang et al. 2023a Future Oncology 19:

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Fulvestrant + Rapamycin (PI3K-Akt-mTOR) pathway inhibitors & Breast Cancer / Mammacarcinoma (HR + / HER2 -)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat